Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Your medication information

Your medication information (SSRI). Paroxetine IR is approved for treating adults with major depressive disorder (MDD), obsessive-compulsive disorder (OCD), panic disorder with or without agoraphobia, social anxiety disorder, generalized anxiety disorder (GAD), and posttraumatic stress disorder (PTSD). Selective serotonin reuptake inhibitor when discontinuing treatment with paroxetine and whenever possible, doses should be reduced gradually. If intolerable symptoms occur following a dose reduction or stopping treatment, then resuming the previously prescribed dose may be considered. Side effects that have been reported with paroxetine discontinuation and other SSRIs include irritability, agitation, dizziness, anxiety, confusion, headache, lethargy, emotional lability, insomnia, and hypomania. Although these events are generally self-limiting, there have been some reports of serious discontinuation symptoms. Common Usage: ContraindiCations: Medications.” See “Interactions with Other sPeCial PoPUlations: Pregnancy and nursing: Tell your doctor if you are pregnant, planning pregnancy, breastfeeding, or planning to breastfeed, as the potential benefits of paroxetine must be weighed against the possible risks to the unborn child or infant. Pediatrics: Paroxetine is not approved for patients younger than 18 years. Geriatrics: There may be a greater sensitivity to paroxetine in elderly patients. SSRIs, including paroxetine, and SNRIs have been associated with clinically significant hyponatremia in elderly patients who may be http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Brown University Psychopharmacology Update Wiley

Your medication information

The Brown University Psychopharmacology Update , Volume 23 (S4) – Apr 1, 2012

Loading next page...
 
/lp/wiley/your-medication-information-L7bABrX2Wu
Publisher
Wiley
Copyright
Copyright © 2012 Wiley Periodicals, Inc., A Wiley Company
ISSN
1068-5308
eISSN
1556-7532
DOI
10.1002/pu.20162
Publisher site
See Article on Publisher Site

Abstract

(SSRI). Paroxetine IR is approved for treating adults with major depressive disorder (MDD), obsessive-compulsive disorder (OCD), panic disorder with or without agoraphobia, social anxiety disorder, generalized anxiety disorder (GAD), and posttraumatic stress disorder (PTSD). Selective serotonin reuptake inhibitor when discontinuing treatment with paroxetine and whenever possible, doses should be reduced gradually. If intolerable symptoms occur following a dose reduction or stopping treatment, then resuming the previously prescribed dose may be considered. Side effects that have been reported with paroxetine discontinuation and other SSRIs include irritability, agitation, dizziness, anxiety, confusion, headache, lethargy, emotional lability, insomnia, and hypomania. Although these events are generally self-limiting, there have been some reports of serious discontinuation symptoms. Common Usage: ContraindiCations: Medications.” See “Interactions with Other sPeCial PoPUlations: Pregnancy and nursing: Tell your doctor if you are pregnant, planning pregnancy, breastfeeding, or planning to breastfeed, as the potential benefits of paroxetine must be weighed against the possible risks to the unborn child or infant. Pediatrics: Paroxetine is not approved for patients younger than 18 years. Geriatrics: There may be a greater sensitivity to paroxetine in elderly patients. SSRIs, including paroxetine, and SNRIs have been associated with clinically significant hyponatremia in elderly patients who may be

Journal

The Brown University Psychopharmacology UpdateWiley

Published: Apr 1, 2012

There are no references for this article.